Accelerate to discover

Homepage>Discover>Duke uses XRAD 225 CX to test radiosensitivity hypothesis

Apr 4, 2024

Here, we assessed the chicken chorioallantoic membrane (CAM) as an alternative to mice for preclinical cancer imaging...

A microthrombus-driven fixed-point cleaved nanosystem for preventing post-thrombolysis recurrence

Apr 3, 2024

A thrombin-responsive and fixed-point cleaved Fu@pep-CLipo was developed for highly efficient and precise thrombolysis...

Webinar: Multimodal Assessment of Hypoxia in Tumors: From the Lab to the Clinic

Apr 2, 2024

25 April 2024, 4PM CET
This webinar will be of interest to multiple profiles in the community of biomedical
...

Multiplexed tissue imaging using the Orion platform to reveal the Spatial Biology of Cancer

Mar 27, 2024

In this webinar Prof. Sandro Santagata, will reveal how Orion high-plex imaging and the use of this data, is valuable...

Apr 19, 2024

A 19-color single-tube Full Spectrum Flow Cytometry for the detection of Acute Myeloid Leukemia

Mar 13, 2024

This recent publication in Cytometry Part A describes the development and comprehensive workflow of a single-tube,...

18F-labeled somatostatin analogs for somatostatin receptors (SSTRs) targeted PET imaging of NETs

Mar 11, 2024

A novel 18F-radiolabeled somatostatin analogue, [Al18F]NODA-MPAA-HTA, was synthesized and evaluated for positron...

Discover Yokogawa CellVoyager CQ1: Benchtop High-Content Analysis System

Mar 8, 2024

Unlike flow cytometers, the CellVoyager CQ1 confocal quantitative image cytometer does not require pretreatment such as...

Apr 19, 2024

Real-time and quantitative analysis of Macrophage Phagocytosis with RTCA eSight

Feb 23, 2024

The eSight is currently the only instrument that interrogates cell health and behavior using cellular
impedance
...

Show all topics (10)

Duke uses XRAD 225 CX to test radiosensitivity hypothesis

Oct 18, 2021

Diffuse intrinsic pontine glioma (DIPG) kills more children than any other type of brain tumor. Despite clinical trials testing many chemotherapeutic agents, palliative radiotherapy remains the standard treatment. In this paper, tumor genotype dictates radiosensitization after ATM deletion in primary brainstem glioma models. While these tumors need more study, getting greater response rates with existing compounds is immediately translatable to the clinic. Here our friends at Duke, use XRAD 225 CX to test their hypothesis that greater radiosensitivity will lead to better response rates. Read it for yourself:

Do you want to learn more? Read the whole article or just ask us!

Scientific paper

Application

Get more info